Our current study for the first time demonstrated a correlation between the expression levels of RBM5, EGFR and KRAS in NSCLC tissues, with the data suggesting that disruption of RBM5 apoptosis-induced activity and tumor suppressor function is consistent with the potent oncogenic activity associated with EGFR and KRAS overexpression. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.